AJM300, an a4-Integrin Antagonist, Effective as Induction Therapy in Ulcerative Colitis
Investigators examined the safety and efficacy of a small-molecule α4-integrin antagonist, called AJM300, for treating ulcerative colitis.
Investigators examined the safety and efficacy of a small-molecule α4-integrin antagonist, called AJM300, for treating ulcerative colitis.
Researchers sought to evaluate the efficacy of gastroparesis peroral endoscopic myotomy (G-POEM) after 4 years of follow up.
A study was conducted to evaluate sex and racial differences related to emergency department examinations among young adults with chest pain.
A team of researchers sought to determine the predictive value of DICA classification and CODA score for clinical outcomes of diverticulosis.
A team of researchers examined the effects on the microbiome from daily long-term consumption of high-protein, drained yogurt in women with overweight and obesity.
Participants in this study were evaluated for sleep features using a combined heart rate and movement sensor and a subset of participants underwent semi-structured interviews to assess demographics and psychosocial measures.
A team of researchers analyzed the virologic response of hepatitis C virus to direct-acting antivirals in patients with HIV.
A team of researchers assessed long-term risk and predictors for colectomy in patients with acute severe UC in clinical remission post-treatment.
David Dickerson, MD, chair of the ASA Committee on Pain Medicine, discusses suggested changes and recommendations to the proposed clinical practice guidelines for prescribing opioids that were recently issued by the CDC.
Presenting at DDW 2022, researchers evaluated data from the PRISM3 placebo-controlled trial and the PRISM-EXT open-label extension trial of CP101, an investigational microbiome therapeutic.